Form 4: EXAS Director Sells 12,000 Shares Under 10b5-1 Plan

Exact Sciences Director Katherine S. Zanotti sold 12,000 shares of common stock for $65 per share, reducing her direct beneficial ownership to 60,759 shares.

Summary

• Katherine S. Zanotti, a Director of Exact Sciences Corp (EXAS), reported a transaction involving the company's common stock.
• On October 24, 2025, Ms. Zanotti disposed of 12,000 shares of common stock.
• The shares were sold at a price of $65 per share.
• Following this transaction, Ms. Zanotti directly beneficially owns 60,759 shares of Exact Sciences common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was entered into on November 25, 2024.

Sentiment

Score: 5

Explanation: The sale of shares by a director, while a reduction in insider ownership, was executed pursuant to a pre-arranged Rule 10b5-1 trading plan. This typically indicates a non-discretionary transaction for personal financial planning rather than a change in outlook on the company's prospects, leading to a neutral sentiment.

Negatives

• Director Katherine S. Zanotti disposed of 12,000 shares of common stock, reducing her direct beneficial ownership in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may note the reduction in a director's direct ownership, though the pre-arranged nature of the sale under a 10b5-1 plan mitigates its signaling effect regarding company prospects.

Key Dates

Recommendation

The reported transaction is a pre-scheduled sale by a director under a Rule 10b5-1 trading plan. Such sales are typically for personal financial management and do not necessarily reflect a change in the director's view of the company's future performance. Therefore, this single transaction alone does not warrant a change in investment recommendation, and a 'hold' stance is maintained, pending further fundamental analysis.

Keywords

EXAS, Exact Sciences, Insider Trading, Form 4, Stock Sale, Director, Katherine Zanotti, 10b5-1 Plan